Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer

Ramzi G. Salloum, Thomas J Smith, Gail A. Jensen, Jennifer Elston Lafata

Research output: Contribution to journalArticle

Abstract

Background: Evidence-based guidelines recommend chemotherapy for medically fit patients with stages II-IV non-small cell lung cancer (NSCLC). Adherence to chemotherapy guidelines has rarely been studied among large populations, mainly because performance status (PS), a key component in assessing chemotherapy appropriateness, is missing from claims-based datasets. Among a large cohort of patients with known PS, we describe first line chemotherapy use relative to guideline recommendations and identify patient factors associated with guideline concordant use. Patients and methods: Insured patients, ages 50+, with stages II-IV NSCLC between 2000 and 2007 were identified via tumor registry (n= 406). Chart abstracted PS, automated medical claims, Census tract information, and travel distance were linked to tumor registry data. Chemotherapy was considered appropriate for patients with PS 0-2. Multivariate logit models were fit to evaluate patient characteristics associated with chemotherapy over- and under-use per guideline recommendations. Tests of statistical significance were two sided. Results: Overall compliance with first line chemotherapy guidelines was 71%. Significant (p<0.05) predictors of chemotherapy underuse (19%) included increasing age (odds ratio [OR], 1.09), higher income (OR, 1.02), diagnosed before 2003 (OR, 2.05), and vehicle access (OR, 6.96) in the patient's neighborhood. Significant predictors of chemotherapy overuse (10%) included decreasing age (OR, 0.92), diagnosed after 2003 (OR, 3.24), and higher income (OR, 1.05) in the patient's neighborhood. Among NSCLC patients 29% do not receive guideline recommended chemotherapy treatment missing opportunities for cure or beneficial palliation, or receiving chemotherapy with more risk of harm than benefit. Care concordant with guidelines is influenced by age, economic considerations such as income and transportation barriers.

Original languageEnglish (US)
Pages (from-to)255-260
Number of pages6
JournalLung Cancer
Volume75
Issue number2
DOIs
StatePublished - Feb 2012
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Guidelines
Drug Therapy
Odds Ratio
Registries
Censuses
Neoplasms
Logistic Models
Economics

Keywords

  • Chemotherapy
  • Guideline adherence
  • Non-small cell lung cancer
  • Overuse
  • Performance status
  • Underuse

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer. / Salloum, Ramzi G.; Smith, Thomas J; Jensen, Gail A.; Lafata, Jennifer Elston.

In: Lung Cancer, Vol. 75, No. 2, 02.2012, p. 255-260.

Research output: Contribution to journalArticle

Salloum, Ramzi G. ; Smith, Thomas J ; Jensen, Gail A. ; Lafata, Jennifer Elston. / Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer. In: Lung Cancer. 2012 ; Vol. 75, No. 2. pp. 255-260.
@article{6d6d1184240f47339aab648e3a23fa88,
title = "Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer",
abstract = "Background: Evidence-based guidelines recommend chemotherapy for medically fit patients with stages II-IV non-small cell lung cancer (NSCLC). Adherence to chemotherapy guidelines has rarely been studied among large populations, mainly because performance status (PS), a key component in assessing chemotherapy appropriateness, is missing from claims-based datasets. Among a large cohort of patients with known PS, we describe first line chemotherapy use relative to guideline recommendations and identify patient factors associated with guideline concordant use. Patients and methods: Insured patients, ages 50+, with stages II-IV NSCLC between 2000 and 2007 were identified via tumor registry (n= 406). Chart abstracted PS, automated medical claims, Census tract information, and travel distance were linked to tumor registry data. Chemotherapy was considered appropriate for patients with PS 0-2. Multivariate logit models were fit to evaluate patient characteristics associated with chemotherapy over- and under-use per guideline recommendations. Tests of statistical significance were two sided. Results: Overall compliance with first line chemotherapy guidelines was 71{\%}. Significant (p<0.05) predictors of chemotherapy underuse (19{\%}) included increasing age (odds ratio [OR], 1.09), higher income (OR, 1.02), diagnosed before 2003 (OR, 2.05), and vehicle access (OR, 6.96) in the patient's neighborhood. Significant predictors of chemotherapy overuse (10{\%}) included decreasing age (OR, 0.92), diagnosed after 2003 (OR, 3.24), and higher income (OR, 1.05) in the patient's neighborhood. Among NSCLC patients 29{\%} do not receive guideline recommended chemotherapy treatment missing opportunities for cure or beneficial palliation, or receiving chemotherapy with more risk of harm than benefit. Care concordant with guidelines is influenced by age, economic considerations such as income and transportation barriers.",
keywords = "Chemotherapy, Guideline adherence, Non-small cell lung cancer, Overuse, Performance status, Underuse",
author = "Salloum, {Ramzi G.} and Smith, {Thomas J} and Jensen, {Gail A.} and Lafata, {Jennifer Elston}",
year = "2012",
month = "2",
doi = "10.1016/j.lungcan.2011.07.005",
language = "English (US)",
volume = "75",
pages = "255--260",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer

AU - Salloum, Ramzi G.

AU - Smith, Thomas J

AU - Jensen, Gail A.

AU - Lafata, Jennifer Elston

PY - 2012/2

Y1 - 2012/2

N2 - Background: Evidence-based guidelines recommend chemotherapy for medically fit patients with stages II-IV non-small cell lung cancer (NSCLC). Adherence to chemotherapy guidelines has rarely been studied among large populations, mainly because performance status (PS), a key component in assessing chemotherapy appropriateness, is missing from claims-based datasets. Among a large cohort of patients with known PS, we describe first line chemotherapy use relative to guideline recommendations and identify patient factors associated with guideline concordant use. Patients and methods: Insured patients, ages 50+, with stages II-IV NSCLC between 2000 and 2007 were identified via tumor registry (n= 406). Chart abstracted PS, automated medical claims, Census tract information, and travel distance were linked to tumor registry data. Chemotherapy was considered appropriate for patients with PS 0-2. Multivariate logit models were fit to evaluate patient characteristics associated with chemotherapy over- and under-use per guideline recommendations. Tests of statistical significance were two sided. Results: Overall compliance with first line chemotherapy guidelines was 71%. Significant (p<0.05) predictors of chemotherapy underuse (19%) included increasing age (odds ratio [OR], 1.09), higher income (OR, 1.02), diagnosed before 2003 (OR, 2.05), and vehicle access (OR, 6.96) in the patient's neighborhood. Significant predictors of chemotherapy overuse (10%) included decreasing age (OR, 0.92), diagnosed after 2003 (OR, 3.24), and higher income (OR, 1.05) in the patient's neighborhood. Among NSCLC patients 29% do not receive guideline recommended chemotherapy treatment missing opportunities for cure or beneficial palliation, or receiving chemotherapy with more risk of harm than benefit. Care concordant with guidelines is influenced by age, economic considerations such as income and transportation barriers.

AB - Background: Evidence-based guidelines recommend chemotherapy for medically fit patients with stages II-IV non-small cell lung cancer (NSCLC). Adherence to chemotherapy guidelines has rarely been studied among large populations, mainly because performance status (PS), a key component in assessing chemotherapy appropriateness, is missing from claims-based datasets. Among a large cohort of patients with known PS, we describe first line chemotherapy use relative to guideline recommendations and identify patient factors associated with guideline concordant use. Patients and methods: Insured patients, ages 50+, with stages II-IV NSCLC between 2000 and 2007 were identified via tumor registry (n= 406). Chart abstracted PS, automated medical claims, Census tract information, and travel distance were linked to tumor registry data. Chemotherapy was considered appropriate for patients with PS 0-2. Multivariate logit models were fit to evaluate patient characteristics associated with chemotherapy over- and under-use per guideline recommendations. Tests of statistical significance were two sided. Results: Overall compliance with first line chemotherapy guidelines was 71%. Significant (p<0.05) predictors of chemotherapy underuse (19%) included increasing age (odds ratio [OR], 1.09), higher income (OR, 1.02), diagnosed before 2003 (OR, 2.05), and vehicle access (OR, 6.96) in the patient's neighborhood. Significant predictors of chemotherapy overuse (10%) included decreasing age (OR, 0.92), diagnosed after 2003 (OR, 3.24), and higher income (OR, 1.05) in the patient's neighborhood. Among NSCLC patients 29% do not receive guideline recommended chemotherapy treatment missing opportunities for cure or beneficial palliation, or receiving chemotherapy with more risk of harm than benefit. Care concordant with guidelines is influenced by age, economic considerations such as income and transportation barriers.

KW - Chemotherapy

KW - Guideline adherence

KW - Non-small cell lung cancer

KW - Overuse

KW - Performance status

KW - Underuse

UR - http://www.scopus.com/inward/record.url?scp=84855450604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855450604&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2011.07.005

DO - 10.1016/j.lungcan.2011.07.005

M3 - Article

VL - 75

SP - 255

EP - 260

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -